- Conditions
- Metastatic Melanoma, Absence of CNS Metastases
- Interventions
- Proteasome siRNA and tumor antigen RNA-transfected dendritic cells
- Biological
- Lead sponsor
- Scott Pruitt
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 913–936
of 2,695
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Multiple Myeloma
- Interventions
- Tumor Cell Collection, Autologous Stem Cell Transplant, Melphalan, Leukapheresis, Myeloma vaccine, GM-CSF, Lenalidomide
- Procedure · Drug · Biological
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 203 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 15
- States / cities
- San Francisco, California • Atlanta, Georgia • Baltimore, Maryland + 11 more
- Conditions
- COPD, Cystic Fibrosis, Pulmonary Fibrosis
- Interventions
- Plerixafor mobilization of autologous CD117 stem cells
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Chondral Defect, Osteochondritis Dissecans (OCD), Articular Cartilage Defect, Articular Cartilage Disorder of Knee
- Interventions
- MACI, microfracture
- Biological · Procedure
- Lead sponsor
- Vericel Corporation
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2030
- U.S. locations
- 14
- States / cities
- Palo Alto, California • Sacramento, California • New Orleans, Louisiana + 9 more
- Conditions
- Systemic Sclerosis
- Interventions
- Cyclophosphamide, Mesna, G-CSF, Leukopheresis, Total Body Irradiation
- Drug · Procedure
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2004
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Multiple Myeloma
- Interventions
- elotuzumab, Lenalidomide, Dexamethasone, autologous stem cell transplantation
- Drug · Procedure
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 6
- States / cities
- Denver, Colorado • Bethesda, Maryland • Kansas City, Missouri + 3 more
- Conditions
- Lymphoma
- Interventions
- rituximab, yttrium Y 90 ibritumomab tiuxetan
- Biological · Radiation
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years to 120 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2008
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Acute Burns
- Interventions
- Magellan®, Placebo Saline Gel and Usual and Customary Standard of Care
- Device · Other
- Lead sponsor
- Arteriocyte, Inc.
- Industry
- Eligibility
- 18 Years to 86 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 3
- States / cities
- Sacramento, California • Washington D.C., District of Columbia • Salt Lake City, Utah
- Conditions
- Malignant Glioma, High Grade Glioma
- Interventions
- TTRNA-DC vaccines with GM-CSF, Dose-intensified TMZ, Autologous Hematopoietic Stem cells (HSCs), TTRNA-xALT, Td vaccine
- Biological · Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Washington D.C., District of Columbia • Gainesville, Florida
- Conditions
- Osteoarthritis of the Knee
- Interventions
- Autologous bone marrow aspirate concentrate (BMAC), Corticosteroid injections, Crossover Autologous bone marrow aspirate concentrate (BMAC)
- Other · Drug
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- CD 19+ Acute Leukemia
- Interventions
- T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC)
- Biological
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2033
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Leukemia
- Interventions
- aldesleukin, filgrastim, busulfan, cyclophosphamide, etoposide, melphalan, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Herbert Irving Comprehensive Cancer Center
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2008
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Lysosomal Storage Diseases, Cystinosis
- Interventions
- CTNS-RD-04 (including CTNS-RD-04-LB manufactured with LentiBOOST)
- Genetic
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Germ Cell Tumor, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- keyhole limpet hemocyanin, tetanus toxoid
- Biological
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2010
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Oropharyngeal Dysphagia
- Interventions
- Other: No Intervention (subjects were previously treated with Iltamiocel). This is a observational study and all participants will be observed with no intervention.
- Other
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 2
- States / cities
- Sacramento, California • San Francisco, California
- Conditions
- Lymphoma
- Interventions
- Brentuximab vedotin, Rituximab
- Biological
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 16 Years to 100 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Hodgkin Disease, Non-Hodgkins Lymphoma
- Interventions
- Infusion of EBV Specific Cytotoxic T-Lymphocytes
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Not listed
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2006
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Ixazomib, Rituximab
- Drug · Biological
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Interventions
- Blinatumomab, Pembrolizumab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 3
- States / cities
- La Jolla, California • Charleston, South Carolina • Greenville, South Carolina
- Conditions
- Lymphoma, Quality of Life
- Interventions
- Not listed
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2011
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Complication of Transplant
- Interventions
- transplant with early palliative care
- Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Carcinoma, Non-Small-Cell Lung, Metastatic Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Adenocarcinoma of Lung, Large Cell Lung Cancer
- Interventions
- Fludarabine, Cyclophosphamide, CISH Inactivated TIL, Aldesleukin, Pembrolizumab
- Drug · Biological
- Lead sponsor
- Intima Bioscience, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 2
- States / cities
- Duarte, California • Minneapolis, Minnesota
- Conditions
- HIV Infection, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Plasmablastic Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Follicular Lymphoma, Stage III Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage IV Follicular Lymphoma, Stage IV Mantle Cell Lymphoma
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine, Etoposide, Laboratory Biomarker Analysis, Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells, Melphalan, Peripheral Blood Stem Cell Transplantation
- Procedure · Drug · Other + 1 more
- Lead sponsor
- AIDS Malignancy Consortium
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2036
- U.S. locations
- 4
- States / cities
- La Jolla, California • Sacramento, California • San Francisco, California + 1 more
- Conditions
- Epithelial Ovarian Cancer
- Interventions
- MUC1 Dendritic Cell Vaccine (Cvac)
- Biological
- Lead sponsor
- Prima BioMed Ltd
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 5
- States / cities
- Greenbrae, California • La Jolla, California • Boca Raton, Florida + 2 more